{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T08:13:02Z","timestamp":1788509582817,"version":"build-2803163510"},"reference-count":18,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Technology"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:p>\n                    Treatment of extensively drug-resistant (XDR) organisms is complicated by pharmacodynamic and pharmacokinetic (PK) limitations of current antimicrobial agents. Prostatitis is an infection that is historically difficult to treat with beta-lactams given poor tissue penetration as compared to fluoroquinolones and sulfamethoxazole-trimethoprim. Cefiderocol is a novel cephalosporin that is often used to treat a wide variety of gram-negative bacteria that have extensive resistance to other antibiotics. Cefiderocol remains stable against many \u03b2-lactamases and shows enhanced bacterial cell entry as a result of siderophore uptake. However, its penetration into prostatic tissue has not been studied. This review presents the use of cefiderocol in a patient with complicated urinary tract infection and prostatitis caused by XDR\n                    <jats:italic toggle=\"yes\">Klebsiella pneumoniae<\/jats:italic>\n                    resistant to almost all tested antibiotics, including novel beta-lactam\/beta-lactamase combinations. Although PK data suggest that cefiderocol may achieve therapeutic concentrations in prostatic tissue, further studies are needed to confirm its efficacy in treating prostatitis, particularly in cases of chronic or complicated infection. This case highlights cefiderocol as a potential therapeutic option for XDR\n                    <jats:italic toggle=\"yes\">Enterobacterales<\/jats:italic>\n                    prostatitis, though additional research is required to fully understand its prostate penetration and clinical outcomes.\n                  <\/jats:p>","DOI":"10.1177\/87551225261443444","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T12:14:11Z","timestamp":1777464851000},"page":"258-262","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Utilization of Cefiderocol in a Case of Extensively Drug-Resistant\n                    <i>Klebsiella pneumoniae<\/i>\n                    Prostatitis and Recurrent Urinary Tract Infection"],"prefix":"10.1177","volume":"42","author":[{"given":"Nicole","family":"Sunshine","sequence":"first","affiliation":[{"name":"Henry Ford Health, Detroit, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel M.","family":"Kenney","sequence":"additional","affiliation":[{"name":"Henry Ford Health, Detroit, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8000-8453","authenticated-orcid":false,"given":"Nathan A.","family":"Everson","sequence":"additional","affiliation":[{"name":"Henry Ford Health, Detroit, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita B.","family":"Shallal","sequence":"additional","affiliation":[{"name":"Henry Ford Health, Detroit, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5967-5211","authenticated-orcid":false,"given":"Michael P.","family":"Veve","sequence":"additional","affiliation":[{"name":"Henry Ford Health, Detroit, MI, USA"},{"name":"Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01884-13"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1159\/000074526"},{"key":"e_1_3_2_4_2","first-page":"63","article-title":"Tissue penetration of the fourth generation parenteral cephalosporins","author":"Wise R.","year":"1996","unstructured":"Wise R. Tissue penetration of the fourth generation parenteral cephalosporins. J Chemother. 1996;8 suppl 2:63-70.","journal-title":"J Chemother"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005392-199502000-00076"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01676-5"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/29.4.473"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-1055-2"},{"key":"e_1_3_2_9_2","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing, M100","author":"CLSI","year":"2024","unstructured":"CLSI. Performance Standards for Antimicrobial Susceptibility Testing, M100. 34th ed. Clinical and Laboratory Standards Institute; 2024.","edition":"34"},{"key":"e_1_3_2_10_2","unstructured":"Shionogi Inc. Fetroja\u00ae (Cefiderocol) for Injection for Intravenous Use. Prescribing Information. Shionogi Inc; 2019. Accessed May 26 2025. https:\/\/www.shionogimedical.com\/resources\/product\/fetroja-cefiderocol"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsps.2023.06.008"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.37201\/req\/s02.04.2022"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-021-01063-5"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.3390\/cimb46120846"},{"key":"e_1_3_2_15_2","volume-title":"Breakpoint Tables for Interpretation of MICs and Zone Diameters, Version 15.0","author":"The European Committee on Antimicrobial Susceptibility Testing (EUCAST)","year":"2025","unstructured":"The European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint Tables for Interpretation of MICs and Zone Diameters, Version 15.0. EUCAST; 2025."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.5455\/jtomc.2016.03.041"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/dc.10166"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.4081\/rt.2012.e25"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijscr.2024.110776"}],"container-title":["Journal of Pharmacy Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/87551225261443444","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/87551225261443444","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/87551225261443444","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T07:22:30Z","timestamp":1788506550000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/87551225261443444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1177\/87551225261443444"],"URL":"https:\/\/doi.org\/10.1177\/87551225261443444","relation":{},"ISSN":["8755-1225","1549-4810"],"issn-type":[{"value":"8755-1225","type":"print"},{"value":"1549-4810","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]}}}